• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jon Cohen and Michael Hansen Join Talkspace's Board of Directors

    9/15/22 4:05:00 PM ET
    $OPK
    $TALK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $OPK alert in real time by email

    NEW YORK, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Shareholders of Talkspace, Inc. (NASDAQ:TALK) today elected Jon Cohen, M.D., to the virtual behavioral healthcare company's board of directors and approved all other shareholder proposals during the company's first Annual Meeting of Stockholders.

    Dr. Cohen is prior Executive Chairman and Chief Executive Officer of BioReference Laboratories and Senior Vice President of OPKO Health (NASDAQ:OPK). Dr. Cohen brings 30 years of healthcare industry strategy and operating experience to Talkspace's board of directors. He succeeds Jeffrey Crowe as an independent Class I Director with a term expiring in 2025.

    Additionally, the Company's board appointed Cengage Group Chief Executive Officer Michael Hansen to complete Charles Berg's term as a Class II director expiring in 2023. Mr. Hansen, a digital transformation expert, previously served as partner and Chairman at the Boston Consulting Group's digital convergence practice. He's been named one of Fast Company's Most Creative People in Business and twice been recognized as a top CEO by Glassdoor.

    Finally, Talkspace shareholders approved the following proposals, all of which were supported by the Board:

    • Re-election of Erez Shachar and Madhu Pawar as independent Class I directors with terms expiring in 2025;



    • Ratification of appointment of independent auditors; and



    • Approval of current year's executive compensation and approval of review of executive compensation on an annual basis going forward.

    About Talkspace

    Talkspace (NASDAQ:TALK) is a leading virtual behavioral healthcare company committed to helping people lead healthier, happier lives through access to high-quality mental healthcare. At Talkspace, we believe that mental healthcare is core to overall healthcare and should be available to everyone.

    Talkspace pioneered the ability to text with a licensed therapist from anywhere and now offers a comprehensive suite of mental health services from self-guided products to individual, couples and family therapy, in addition to psychiatric treatment and medication management. With Talkspace's core psychotherapy offering, members are matched with one of thousands of licensed providers across all 50 states and can choose from a variety of subscription plans including video, text or audio chat sessions and/or unlimited text messaging.

    All care offered at Talkspace is delivered through an easy-to-use, fully-encrypted web and mobile platform that meets HIPAA, federal, and state regulatory requirements. Talkspace covered approximately 77 million lives at June 30, 2022, through our partnerships with employers, health plans, and paid benefits programs.

    For more information, visit www.talkspace.com.

    Contacts

    ‍For Investors:

    Mike Lovell, Senior Director Investor Relations

    515-771-1585

    Mike.Lovell@Talkspace.com

    For Media:

    SKDK

    John Kim

    310-997-5963

    jkim@skdknick.com 



    Primary Logo

    Get the next $OPK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OPK
    $TALK

    CompanyDatePrice TargetRatingAnalyst
    OPKO Health Inc.
    $OPK
    4/29/2026Outperform → Mkt Perform
    Barrington Research
    Talkspace Inc.
    $TALK
    12/9/2025$3.50Equal Weight
    Barclays
    OPKO Health Inc.
    $OPK
    11/20/2025Neutral
    Analyst
    OPKO Health Inc.
    $OPK
    10/31/2025$1.60Buy → Hold
    Jefferies
    Talkspace Inc.
    $TALK
    10/31/2025$5.00Hold → Buy
    Needham
    OPKO Health Inc.
    $OPK
    4/25/2025Neutral
    Analyst
    Talkspace Inc.
    $TALK
    4/3/2025$5.00Buy
    Canaccord Genuity
    Talkspace Inc.
    $TALK
    12/9/2024$4.50Overweight
    KeyBanc Capital Markets
    More analyst ratings

    $OPK
    $TALK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026

    EB612, a first-in-class long-acting PTH(1-34) oral peptide  for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618, a first-in-class dual GLP-1/glucagon oral receptor agonist (oxyntomodulin) for obesity and metabolic disorders, showed dose-proportional pharmacokinetics and a robust effect on blood glucose in non-human primates TEL AVIV, June 16, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera"), a leader in the development of oral peptides, reported preclinical data at ENDO 2026, the annual meeting of the Endocrine Society, for its EB612 and EB618 pipeline programs. Bo

    6/16/26 8:33:11 AM ET
    $ENTX
    $OPK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026

    MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual meeting. The poster, "Production and Characterization of OPK8801001, a Novel Long-Acting hGH Receptor Antagonist for the Treatment of Acromegaly," available here, was presented by Moran Golan, Ph.D., Director of Preclinical & Clinical Pharmacology at OPKO Biologics. In vivo data showed that OPK8801001 produced robust, dose-dependent, sustained suppression of insulin-like growth factor-1 (IGF-1), a marker of disease activity in acromegaly. The findings suggest the potential for a weekly alterna

    6/15/26 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talkspace Announces 'Tee,' the First Safe AI Agent Specifically Developed to Help Individuals Navigate Life's Daily Mental Health Challenges

    By combining proprietary clinical algorithms, rigorously tested safety features, and proven therapy techniques, Tee provides a trustworthy, confidential alternative for people using general-purpose AI chatbots for supportive conversations Talkspace (NASDAQ:TALK), a leading online behavioral healthcare provider, today announced Tee, a safe, fine-tuned large language model developed by mental health experts. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260609734252/en/ With HIPAA-grade privacy protections, Tee has the ability to identify potential suicide risk, homicidal/violence risk, abuse risk and seven other mental health

    6/9/26 8:30:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $OPK
    $TALK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & Chairman Frost Phillip Md Et Al bought $768,807 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/21/25 5:07:09 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $771,328 worth of shares (580,000 units at $1.33) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/20/25 6:10:53 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & Chairman Frost Phillip Md Et Al bought $759,115 worth of shares (580,000 units at $1.31) (SEC Form 4)

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    11/19/25 5:02:21 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $TALK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer, Secretary Reilly John Charles sold $209,515 worth of shares (40,289 units at $5.20), decreasing direct ownership by 4% to 1,017,686 units (SEC Form 4)

    4 - Talkspace, Inc. (0001803901) (Issuer)

    6/22/26 9:30:04 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Director Lachman Prem A

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    6/22/26 5:38:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Medel Roger Md

    4 - OPKO HEALTH, INC. (0000944809) (Issuer)

    6/22/26 5:37:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $TALK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Opko Health downgraded by Barrington Research

    Barrington Research downgraded Opko Health from Outperform to Mkt Perform

    4/29/26 7:41:04 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Talkspace with a new price target

    Barclays initiated coverage of Talkspace with a rating of Equal Weight and set a new price target of $3.50

    12/9/25 8:53:40 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Analyst initiated coverage on Opko Health

    Analyst initiated coverage of Opko Health with a rating of Neutral

    11/20/25 8:08:07 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $TALK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by OPKO Health Inc.

    SCHEDULE 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    7/1/26 4:04:37 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Talkspace Inc.

    25-NSE - Talkspace, Inc. (0001803901) (Subject)

    6/22/26 3:55:15 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    OPKO Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - OPKO HEALTH, INC. (0000944809) (Filer)

    6/18/26 4:06:31 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $TALK
    Financials

    Live finance-specific insights

    View All

    OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results

    MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first quarter of 2026 and recent weeks included the following: Initiated and completed first dose cohort of MDX2301 Phase 1 clinical trial for the prevention of COVID-19. MDX2301 is a tetravalent bispecific antibody that neutralizes all known variants of SARS-CoV-2 and also has the potential to delay resistance by emerging variants. The Phase 1 clinical trial (NCT07445971) is evaluating the safety, pharmacokinetics and tolerability of MDX2301 administered via different routes in healthy volunteers

    4/28/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026

    MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on Tuesday, April 28, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 28th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants to pre-register for the conference call using this link. Callers who pre-register will receive a unique PIN to gain immediate access to the call and bypass the live operator. Participants

    4/21/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results

    MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies. This new partnership leverages ModeX's MSTAR technology platform with Regeneron's proprietary binders to develop single molecule candidates that target multiple distinct biological pathways in several clinical indications. ModeX received an upfront

    2/26/26 4:05:00 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OPK
    $TALK
    Leadership Updates

    Live Leadership Updates

    View All

    OPKO Health's ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development

    WESTON, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO Health, Inc. (NASDAQ:OPK) company, today announced the appointment of Giovanni Abbadessa, M.D., Ph.D. as Chief Medical Officer, a newly created position. Dr. Abbadessa has over two decades of experience in drug development, including most recently as Vice President at Sanofi, where he provided executive leadership for advancing oncology assets. "Dr. Abbadessa's deep experience in leading early-stage oncology development makes him the ideal fit to steer development of our multispecific antibodies for cancer and other clinical indications," said Dr. Gary Nabel, co-founder, President and CEO of ModeX Thera

    9/23/24 8:00:00 AM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talkspace Partners With Amazon Health Services to Help Millions Discover Mental Health Benefits

    New collaboration aims to improve awareness of, and expand access to, online therapy and psychiatry services to the 150+ million people who have Talkspace as a covered benefit Talkspace (NASDAQ:TALK), a leading online behavioral health care company, today announced a partnership with Amazon Health Services to increase awareness and discoverability of its mental health care services on Amazon.com. Talkspace is the first virtual behavioral health provider to join Amazon Health Services' program to help individuals discover and enroll in their health insurance benefits at no extra cost or for a small copay. With more than 5,000 therapists and providers across 50 states, Talkspace improves acc

    9/17/24 8:00:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    Talkspace and the Professional Tennis Players Association Join Forces to Support Mental Health of Athletes Year Round

    Today, Talkspace (NASDAQ:TALK), a leading online behavioral health care company, announced its partnership with the Professional Tennis Players Association (PTPA), global advocates for professional tennis players. Talkspace will serve as the PTPA's exclusive mental health technology partner, granting players, their families, and their support teams free, 24/7 access to Talkspace's self-guided therapy app, Talkspace Go, as well as discounted access to its virtual therapy offering. "Talkspace is honored to join forces with the PTPA as its exclusive mental health provider, dedicated to delivering high-quality, evidence-based support where and when players need it. This collaboration undersco

    8/28/24 9:06:00 AM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $OPK
    $TALK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by OPKO Health Inc.

    SC 13D/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/15/24 4:39:33 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by OPKO Health Inc.

    SC 13G - OPKO HEALTH, INC. (0000944809) (Subject)

    11/13/24 4:30:24 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by OPKO Health Inc.

    SC 13G/A - OPKO HEALTH, INC. (0000944809) (Subject)

    11/12/24 4:54:06 PM ET
    $OPK
    Biotechnology: Pharmaceutical Preparations
    Health Care